Radionuclide-loaded nanoparticles for focal tissue ablation
AssigneeTranslational and Fundamental Technologies Institute LLC
InventorBashir Akhavan Tafti
Life of this patent
Estimating the term…
Abstract
The present disclosure features radiopharmaceutical compositions including a radionuclide and an imaging agent encapsulated within, embedded in, or conjugated to a nanoparticle (e.g., via a complexing moiety, such as a chelator), and methods of their use. The radiopharmaceuticals may be formulated for direct administration to the diseased tissue, with minimal or no washout of the radiopharmaceutical to non-target sites within a subject. The radiopharmaceuticals of the present disclosure allow for efficient treatment of diseased tissue proximal to the site of administration with minimal to no damage to the surrounding tissue.
Claims28
A radiopharmaceutical comprising:
- (a) a plurality of non-encapsulated nanoparticles, each comprising a matrix with an exterior surface;
- (b) an imaging agent;
- (c) a radionuclide bound to a chelating agent;
- and
- (d) a cell-penetrating ligand;
- wherein, for each nanoparticle of the plurality of nanoparticles, the imaging agent and the radionuclide are encapsulated within the nanoparticle and the cell-penetrating ligand is conjugated to the exterior surface of the nanoparticle,
- wherein each said nanoparticle is from about 1 nm to about 900 nm in diameter,
- wherein the radiopharmaceutical has a radioactivity of greater than 0.125 kBq per mL, and
- wherein the cell-penetrating ligand promotes nuclear localization of the nanoparticle.
Dependencies are inferred from the claim text.